title: Adalimumab versus infliximab in treating post-operative recurrence of Crohn's disease: a national cohort study.
abstract: OBJECTIVE
  Perform a comparison between adalimumab (ADA) and infliximab (IFX) in treating post-operative recurrence of Crohn's disease (a comparative analysis of efficacy and safety).
  
  
  METHODS
  From the 267 patients treated with Adalimumab or Infliximab between January 2005 and June 2014 in Romania, 44 received anti- TNF (tumor necrosis factor) therapy for prevention of post-operative recurrence. A comparison between patients treated with IFX and ADA was made with the Chi- square and t- student test, with the aid of the statistical program Mini Tab 17.
  
  
  RESULTS
  Twenty-one patients received IFX and 23 ADA. This included 49% males (22/44), with a mean age of 41 years, mean disease duration of 6 years, and 84.1% had previously received azathioprine. The IFX group is comparable with the ADA group regarding most of the parameters, except for therapy duration. Mean duration of therapy was 33 months. The rate of complete response was comparable between the two groups: 67% in the IFX group vs. 78.3% in the ADA group, the same as the rate of re-resection, 19.1% vs. 4.4% and the rate of endoscopic recurrence, 29 vs. 33% at 12 months. Risk factors for postoperative recurrence (POR) (male sex, younger age, ileocolonic location, stricturing or penetrating behaviour) were studied, only ileocolonic location was found to be associated with Crohn's disease recurrence in patients treated with ADA.
  
  
  CONCLUSIONS
  Overall infliximab and aalimumab are equally efficient in patients with resected Crohn's disease (CD) with a complete response of 72.7%, a rate of re-resection of 11.4 % and a rate of endoscopic recurrence of 35%. Ileocolonic location might be a predictive factor for loss of response to adalimumab in resected Crohn's disease patients.
authors.affiliation: Department of Gastroenterology and Hepatology, Clinic Fundeni Institute, ROMANIA.
authors.forename: Carmen-Monica
authors.initials: CM
authors.lastname: Preda
authors.affiliation: Department of Gastroenterology and Hepatology, Clinic Fundeni Institute, ROMANIA.
authors.forename: Larisa Elena
authors.initials: LE
authors.lastname: Fulger
authors.affiliation: Clinic of Gastroenterology, Clinic Universitary Emergency Hospital, ROMANIA.
authors.forename: Lucian
authors.initials: L
authors.lastname: Negreanu
authors.affiliation: Department of Gastroenterology and Hepatology, Clinic Fundeni Institute, ROMANIA.
authors.forename: Mircea
authors.initials: M
authors.lastname: Manuc
authors.affiliation: Department of Gastroenterology and Hepatology, Clinic Fundeni Institute.
authors.forename: Irina
authors.initials: I
authors.lastname: Sandra
authors.affiliation: Department of Gastroenterology and Hepatology, Clinic Fundeni Institute, ROMANIA.
authors.forename: Mircea-Mihai
authors.initials: MM
authors.lastname: Diculescu
mesh_terms: D000068879:Adalimumab / Q000627:therapeutic use*; D000293:Adolescent; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D002648:Child; D015331:Cohort Studies; D003424:Crohn Disease / Q000188:drug therapy* / Q000601:surgery; D005260:Female; D006801:Humans; D000069285:Infliximab / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D012189:Retrospective Studies; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000893:Anti-Inflammatory Agents; D000069285:Infliximab; D000068879:Adalimumab